GlassScriptPhysician profile
Melissa Cheng
NPI 1225258130
$9,558.20
in general payments reported to CMS, 2019-2025
32 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,233 · 2022: $1,514 · 2023: $2,415 · 2024: $2,385 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,706 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,706.17 |
| Education | $104.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,569.76 | 2021-2025 | |
| Ucb, INC. | $1,178.89 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,161.02 | 2021-2025 | |
| Janssen Biotech, INC. | $1,037.25 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $698.51 | 2021-2025 | Enbrel, Otezla, Evenity |
| E.R. Squibb & Sons, L.L.C. | $578.52 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $511.73 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $479.42 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.28 | 2021-2024 | Cyltezo, Ofev |
| Lilly USA, LLC | $313.59 | 2021-2024 | Taltz |
| Glaxosmithkline, LLC. | $302.66 | 2021-2025 | Benlysta |
| Radius Health, INC. | $189.83 | 2021-2024 | Tymlos |
| Sobi, INC | $164.43 | 2023-2024 | |
| Sandoz INC. | $155.29 | 2023-2024 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $150.19 | 2021-2024 | Strensiq, Ultomiris |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $137.97 | 2025 | Nemluvio |
| Pfizer INC. | $118.67 | 2022-2025 | |
| Tersera Therapeutics LLC | $56.36 | 2025 | Quzyttir |
| Ani Pharmaceuticals, INC. | $53.07 | 2022 | |
| Horizon Therapeutics Plc | $43.10 | 2022 | |
| Organon LLC | $40.96 | 2021-2022 | |
| Almatica Pharma LLC | $29.37 | 2024 | Teriparatide |
| Takeda Pharmaceuticals U.S.A., INC. | $28.91 | 2022 | |
| Mylan Institutional INC. | $25.91 | 2023 | Hulio |
| Genentech USA, INC. | $25.01 | 2021 | |
| Aurinia Pharma U.S., INC. | $24.33 | 2023 | Lupkynis |
| Endo Pharmaceuticals INC. | $23.68 | 2023 | Xiaflex |
| Fidia Pharma USA INC. | $22.06 | 2024 | Hyalgan |
| Janssen Pharmaceuticals, INC | $20.39 | 2022 | |
| Celgene Corporation | $19.71 | 2021 | |
| Kyowa Kirin, INC. | $17.93 | 2023 | |
| Fresenius Kabi USA, LLC | $13.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.